Transarterial VSV oncolytic therapy for hepatocellular carcinoma

Background Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide, with the majority of clinical cases arising as a result of the wound-healing response to chronic liver injury known as hepatic fibrosis. If left untreated, the condition progresses to the state of cirrhosis with severe complications of end-stage liver disease including HCC. When HCC arises under these conditions, it presents a major clinical challenge for treatment of the cancer as well as the underlying liver disease.